Morgan Stanley
PTCT icon

Morgan Stanley’s PTC Therapeutics PTCT Stock Holding History

Morgan Stanley’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.9M Sell
674,134
-231,058
-26% -$16.4M ﹤0.01% 2189
2025
Q4 		$68.8M Buy
905,192
+485,775
+116% +$35.3M ﹤0.01% 1771
2025
Q3 		$25.7M Sell
419,417
-743,922
-64% -$38.7M ﹤0.01% 2648
2025
Q2 		$56.8M Buy
1,163,339
+213,905
+23% +$10.2M ﹤0.01% 1806
2025
Q1 		$48.4M Sell
949,434
-124,383
-12% -$6.21M ﹤0.01% 1850
2024
Q4 		$48.5M Sell
1,073,817
-84,237
-7% -$3.61M ﹤0.01% 1861
2024
Q3 		$43M Sell
1,158,054
-358,703
-24% -$12M ﹤0.01% 1976
2024
Q2 		$46.4M Sell
1,516,757
-546,284
-26% -$17.7M ﹤0.01% 1833
2024
Q1 		$60M Sell
2,063,041
-429,477
-17% -$12M ﹤0.01% 1594
2023
Q4 		$68.7M Buy
2,492,518
+2,056,778
+472% +$47M ﹤0.01% 2119
2023
Q3 		$9.76M Buy
435,740
+54,664
+14% +$2.03M ﹤0.01% 3148
2023
Q2 		$15.5M Buy
381,076
+155,186
+69% +$7.59M ﹤0.01% 2732
2023
Q1 		$10.9M Sell
225,890
-71,775
-24% -$3.28M ﹤0.01% 3058
2022
Q4 		$11.4M Buy
297,665
+13,416
+5% +$558K ﹤0.01% 2949
2022
Q3 		$14.3M Sell
284,249
-140,138
-33% -$6.87M ﹤0.01% 2581
2022
Q2 		$17M Buy
424,387
+80,853
+24% +$2.84M ﹤0.01% 2462
2022
Q1 		$12.8M Buy
343,534
+127,819
+59% +$4.92M ﹤0.01% 2607
2021
Q4 		$8.59M Buy
215,715
+173,765
+414% +$6.65M ﹤0.01% 3113
2021
Q3 		$1.56M Sell
41,950
-137,531
-77% -$5.65M ﹤0.01% 4764
2021
Q2 		$7.59M Buy
179,481
+160,778
+860% +$6.89M ﹤0.01% 3312
2021
Q1 		$885K Sell
18,703
-33,173
-64% -$1.97M ﹤0.01% 4808
2020
Q4 		$3.17M Buy
51,876
+32,022
+161% +$1.89M ﹤0.01% 3757
2020
Q3 		$927K Sell
19,854
-8,484
-30% -$418K ﹤0.01% 4260
2020
Q2 		$1.44M Sell
28,338
-57,534
-67% -$2.83M ﹤0.01% 3883
2020
Q1 		$3.83M Sell
85,872
-191,059
-69% -$9.62M ﹤0.01% 2709
2019
Q4 		$13.3M Buy
276,931
+216,665
+360% +$9.21M ﹤0.01% 2089
2019
Q3 		$2.04M Buy
60,266
+20,336
+51% +$885K ﹤0.01% 3773
2019
Q2 		$1.8M Buy
39,930
+14,919
+60% +$589K ﹤0.01% 3854
2019
Q1 		$942K Sell
25,011
-74,126
-75% -$2.49M ﹤0.01% 4154
2018
Q4 		$3.4M Sell
99,137
-72,309
-42% -$2.6M ﹤0.01% 3310
2018
Q3 		$8.06M Sell
171,446
-403,743
-70% -$16.7M ﹤0.01% 2647
2018
Q2 		$19.4M Sell
575,189
-36,533
-6% -$1.14M 0.01% 1673
2018
Q1 		$16.6M Buy
611,722
+478,675
+360% +$12.1M ﹤0.01% 1844
2017
Q4 		$2.22M Buy
133,047
+29,357
+28% +$497K ﹤0.01% 3943
2017
Q3 		$2.08M Sell
103,690
-473,167
-82% -$9.26M ﹤0.01% 3845
2017
Q2 		$10.6M Buy
576,857
+501,534
+666% +$6.76M ﹤0.01% 2130
2017
Q1 		$742K Sell
75,323
-219,780
-74% -$2.66M ﹤0.01% 4592
2016
Q4 		$3.22M Buy
295,103
+263,510
+834% +$2.76M ﹤0.01% 3441
2016
Q3 		$442K Buy
31,593
+10,085
+47% +$82K ﹤0.01% 4597
2016
Q2 		$151K Buy
21,508
+10,419
+94% +$76.4K ﹤0.01% 5063
2016
Q1 		$72K Buy
11,089
+5,578
+101% +$96.8K ﹤0.01% 5460
2015
Q4 		$178K Sell
5,511
-59,862
-92% -$1.76M ﹤0.01% 5146
2015
Q3 		$1.75M Buy
65,373
+35,027
+115% +$1.5M ﹤0.01% 3639
2015
Q2 		$1.46M Buy
30,346
+16,116
+113% +$940K ﹤0.01% 3911
2015
Q1 		$866K Sell
14,230
-2,899
-17% -$177K ﹤0.01% 4238
2014
Q4 		$887K Buy
17,129
+5,791
+51% +$255K ﹤0.01% 4244
2014
Q3 		$499K Sell
11,338
-5,079
-31% -$159K ﹤0.01% 4574
2014
Q2 		$430K Buy
16,417
+3,763
+30% +$80.5K ﹤0.01% 4693
2014
Q1 		$331K Buy
12,654
+5,960
+89% +$160K ﹤0.01% 4832
2013
Q4 		$114K Buy
+6,694
New +$118K ﹤0.01% 5307

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Morgan Stanley's PTCT Position: Q1 2026 in Review

Morgan Stanley reduced its PTC Therapeutics (PTCT) stake by 26% in Q1 2026, selling an estimated $16.4M and leaving 674,134 shares worth $45.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2189.

Morgan Stanley first reported a position in PTCT in Q4 2013 and has held it in 50 quarters since. The position peaked at $68.8M in Q4 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Morgan Stanley held 674,134 shares of PTC Therapeutics worth $45.9M as of Q1 2026.
  • Morgan Stanley sold 231,058 PTC Therapeutics shares in Q1 2026, an estimated $16.4M.
  • PTC Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #2189 holding.
  • Morgan Stanley first reported a position in PTC Therapeutics in Q4 2013 and has held it in 50 quarters since.
  • Morgan Stanley's PTC Therapeutics position peaked at $68.8M in Q4 2025.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.